查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797990

2032 年表观遗传学诊断市场预测：按产品、技术、应用、最终用户和地区进行的全球分析

Epigenetic Diagnostics Market Forecasts to 2032 - Global Analysis By Product (Reagents, Kits, Instruments, Enzymes and Services),Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球表观遗传学诊断市场预计在 2025 年达到 192 亿美元，到 2032 年将达到 528 亿美元，预测期内的复合年增长率为 15.5%。

表观遗传诊断利用表观遗传标记（例如DNA甲基化、组蛋白修饰和非编码RNA表现）来检测和监测疾病。与传统的基因检测不同，表观遗传诊断在不改变DNA序列的情况下评估基因表现的调控方式。这种方法可以更早、更准确地检测出癌症、神经系统疾病和自体免疫疾病等疾病。此类诊断方法因其在个人化医疗、治疗监测以及在分子层面上阐明疾病机制的潜力而日益受到重视。

根据美国癌症协会预测，2024年美国将新增201万例癌症病例，约有611,720人死于癌症。

个人化医疗日益受到关注

个人化医疗日益受到关注，这是表观遗传诊断市场的主要驱动力。医疗保健提供者正转向基于个人基因和表观遗传特征的客製化治疗策略。表观遗传诊断能够更早、更准确地检测疾病易感性，帮助临床医师制定个人化治疗性介入。随着以患者为中心的医疗成为主流，对能够提供深入生物学洞察的分子诊断工具的需求持续增长，这使得表观遗传技术成为精准医疗革命的前沿。

表观遗传诊断高成本

表观遗传诊断程序的高成本是市场成长的主要限制因素。对先进定序技术、专用试剂和熟练人员的需求推高了营运成本。这些成本限制了其应用，尤其是在医疗预算有限的中低收入国家。此外，此类检测的报销范围有限，限制了患者的可及性，延缓了其商业化进程，并阻碍了表观遗传诊断在各地区常规临床实践中的广泛应用。

扩展到早期疾病检测

表观遗传诊断在早期疾病检测中有着巨大的应用机会，尤其是在肿瘤学和神经退化性疾病。这些工具可以在症状出现之前检测到基因表现的细微变化，以便及时介入。基于DNA甲基化模式的液态生物检体等非侵入性检测因其高灵敏度和特异性而备受关注。将临床效用扩展到早期诊断，将为改善患者预后和降低长期治疗成本带来变革性的潜力。

资料隐私和道德问题

资料隐私和伦理问题对表观遗传学诊断的推广应用构成重大威胁。敏感遗传和表观遗传数据的收集和分析引发了关于知情同意、数据所有权以及潜在滥用的问题。未经授权存取或共用此类资讯可能导致就业和保险方面的歧视。这些担忧促使人们呼吁建立更严格的法律规范和伦理框架。如果这些问题无法充分解决，可能会损害使用者的信任，并限制这些技术的大规模部署。

COVID-19的影响：

COVID-19 疫情为表观遗传诊断市场带来了挑战和机会。儘管许多地区已暂停非必要诊断检测，但这场危机加速了分子检测技术的创新和投资。关于 COVID-19 对錶观遗传标记影响的研究重新激发了人们对免疫和发炎路径诊断的兴趣。随着医疗保健系统逐渐适应疫情后的现实，越来越多的人将包括表观遗传学在内的先进诊断技术纳入常规实践，以更好地监测疾病并进行风险分层。

试剂市场预计将成为预测期内最大的市场

试剂领域预计将在预测期内占据最大的市场占有率，这得益于其在检测流程中的关键作用。试剂包括试剂套件、酵素、缓衝液、引子等，用于各种工作流程，例如DNA甲基化和染色质免疫沉淀。诊断检测量的增加，加上学术和临床领域研发的不断加强，持续推动需求。试剂在手动和自动化平台上的持续使用，确保了其在整个预测期内保持稳定的市场主导地位。

DNA 甲基化部分预计将在预测期内实现最高复合年增长率

DNA甲基化领域预计将在预测期内实现最高成长率，这得益于其在癌症诊断、神经系统疾病和产前筛检的广泛应用。 DNA甲基化是研究最深入的表观遗传修饰之一，为基因调控和疾病进展提供了重要见解。甲基化特异性PCR和定序平台的技术进步提高了检测准确性。不断增加的研究资金和临床检验的不断深入，进一步推动了该领域在全球市场的快速扩张。

占比最大的地区：

由于医疗基础设施的不断扩张、癌症发病率的上升以及基因组学投资的不断增加，预计亚太地区将在预测期内占据最大的市场占有率。中国、日本和印度等国越来越重视精准医疗和分子诊断。政府对生物技术研发的支持，以及人们对早期疾病检测意识的不断增强，正在推动该地区生物技术的应用。庞大的患者群也推动了临床试验活动和市场渗透。

复合年增长率最高的地区：

在预测期内，北美预计将呈现最高的复合年增长率，这得益于其先进的科研能力、雄厚的医疗资金以及精准医疗的早期应用。领先的生物技术公司和学术机构的存在将推动诊断平台的创新。支持性的法律规范和良好的患者意识将进一步加速临床应用。随着对非侵入性和个人化检测的需求不断增长，北美将继续成为表观遗传学创新、临床试验扩展和商业化的热点。

提供免费客製化：

订阅此报告的用户可获得以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球表观遗传学诊断市场（按产品）

  • 试剂
  • 套件
    • ChIP定序套件
    • 亚硫酸氢盐转化试剂套件
    • RNA定序套件
    • 全基因组扩增试剂套件
  • 装置
  • 酵素
  • 服务

6. 全球表观遗传学诊断市场（按技术）

  • DNA甲基化
  • 组蛋白甲基化
  • 微型RNA修饰
  • 染色质结构
  • 其他技术

7. 全球表观遗传学诊断市场（按应用）

  • 肿瘤学
    • 固态肿瘤
    • 液体肿瘤
  • 非肿瘤学
    • 发炎性疾病
    • 代谢疾病
    • 感染疾病
    • 心血管疾病
  • 其他用途

8. 全球表观遗传诊断市场（依最终用户）

  • 学术研究
  • 临床研究
  • 医院和诊所
  • 製药和生物技术公司
  • 其他最终用户

9. 全球表观遗传学诊断市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要发展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Illumina Inc.
  • Thermo Fisher Scientific
  • QIAGEN NV
  • Merck KGaA（Merck Millipore）
  • Agilent Technologies
  • Bio-Rad Laboratories
  • Abcam PLC
  • PerkinElmer Inc.
  • Active Motif
  • Diagenode SA
  • New England Biolabs
  • Zymo Research Corporation
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GlaxoSmithKline plc
  • Eisai Co. Ltd.
  • Pfizer Inc.
  • Janssen Pharmaceuticals Inc.
Product Code: SMRC30360

According to Stratistics MRC, the Global Epigenetic Diagnostics Market is accounted for $19.2 billion in 2025 and is expected to reach $52.8 billion by 2032 growing at a CAGR of 15.5% during the forecast period. Epigenetic diagnostics involves the use of epigenetic markers-such as DNA methylation, histone modification, and non-coding RNA expression-to detect and monitor diseases. Unlike traditional genetic tests, epigenetic diagnostics assess how gene expression is regulated without altering the DNA sequence. This approach allows for earlier and more precise detection of conditions like cancer, neurological disorders, and autoimmune diseases. These diagnostics are gaining momentum due to their potential in personalized medicine, treatment monitoring, and uncovering disease mechanisms at the molecular level.

According to the American Cancer Society, the estimated number of new cancer cases in the U.S. in 2024 was 2.01 million, with around 6,11,720 deaths caused by cancer.

Market Dynamics:

Driver:

Growing focus on personalized medicine

The increasing emphasis on personalized medicine is a key driver for the epigenetic diagnostics market. Healthcare providers are shifting toward tailored treatment strategies based on individual genetic and epigenetic profiles. Epigenetic diagnostics enable earlier and more accurate detection of disease predispositions, helping clinicians customize therapeutic interventions. As patient-centric care becomes mainstream, demand for molecular diagnostic tools that provide deep biological insights continues to rise, positioning epigenetic technologies at the forefront of the precision medicine revolution.

Restraint:

High cost of epigenetic diagnostic procedures

The high cost associated with epigenetic diagnostic procedures acts as a major restraint on market growth. Advanced sequencing technologies, specialized reagents, and the need for skilled personnel drive up operational expenses. These costs limit adoption, particularly in low- and middle-income countries where healthcare budgets are constrained. Furthermore, limited reimbursement coverage for such tests restricts patient access, slowing commercialization and impeding the broader integration of epigenetic diagnostics into routine clinical practice across diverse regions.

Opportunity:

Expansion into early disease detection

A significant opportunity lies in the application of epigenetic diagnostics for early disease detection, particularly in oncology and neurodegenerative disorders. These tools can detect subtle changes in gene expression before symptoms appear, allowing for timely intervention. Non-invasive tests such as liquid biopsies based on DNA methylation patterns are gaining attention for their high sensitivity and specificity. Expanding clinical utility into early-stage diagnosis offers a transformative potential for improving patient outcomes and reducing long-term treatment costs.

Threat:

Data privacy and ethical concerns

Data privacy and ethical concerns pose substantial threats to the adoption of epigenetic diagnostics. The collection and analysis of sensitive genetic and epigenetic data raise questions about consent, data ownership, and potential misuse. Unauthorized access or sharing of such information could lead to discrimination in employment or insurance. These concerns are prompting calls for stricter regulatory oversight and ethical frameworks, and unless adequately addressed, they may hinder user trust and limit large-scale deployment of these technologies.

Covid-19 Impact:

The COVID-19 pandemic created both challenges and opportunities for the epigenetic diagnostics market. While non-essential diagnostic testing was temporarily paused in many regions, the crisis also accelerated innovation and investment in molecular testing technologies. Research into COVID-19's impact on epigenetic markers sparked renewed interest in immune and inflammatory pathway diagnostics. As healthcare systems adapt to post-pandemic realities, there's growing momentum for integrating advanced diagnostics, including epigenetics, into routine care for better disease monitoring and risk stratification.

The reagents segment is expected to be the largest during the forecast period

The reagents segment is expected to account for the largest market share during the forecast period, owing to its critical role in enabling testing procedures. These include kits, enzymes, buffers, and primers used across various workflows like DNA methylation and chromatin immunoprecipitation. Rising volumes of diagnostic tests, coupled with increased R&D in academic and clinical settings, continue to boost demand. The consistent use of reagents in both manual and automated platforms ensures steady market dominance throughout the forecast period.

The DNA methylation segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the DNA methylation segment is predicted to witness the highest growth rate impelled by, its widespread application in cancer diagnostics, neurological disorders, and prenatal screening. As one of the most studied epigenetic modifications, DNA methylation provides critical insights into gene regulation and disease progression. Technological advancements in methylation-specific PCR and sequencing platforms have improved detection accuracy. Increased research funding and growing clinical validation are further propelling the segment's rapid expansion across global markets.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by expanding healthcare infrastructure, rising cancer incidence, and growing investments in genomics. Countries like China, Japan, and India are increasingly focusing on precision medicine and molecular diagnostics. Government support for biotechnology R&D, along with increased awareness about early disease detection, is spurring regional adoption. The availability of a large patient pool also enhances clinical trial activity and market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to, advanced research capabilities, strong healthcare funding, and early adoption of precision medicine. The presence of major biotechnology companies and academic institutions fosters innovation in diagnostic platforms. Supportive regulatory frameworks and high patient awareness further accelerate clinical implementation. As demand for non-invasive and personalized testing rises, North America remains a hotbed for epigenetics-based innovation, clinical trial expansion, and commercial

Key players in the market

Some of the key players in Epigenetic Diagnostics Market include Illumina Inc., Thermo Fisher Scientific, QIAGEN NV, Merck KGaA (Merck Millipore), Agilent Technologies, Bio-Rad Laboratories, Abcam PLC, PerkinElmer Inc., Active Motif, Diagenode SA, New England Biolabs, Zymo Research Corporation, F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Eisai Co. Ltd., Pfizer Inc. and Janssen Pharmaceuticals Inc.

Key Developments:

In June 2025, Illumina introduced its advanced epigenetic sequencing platform enabling high-throughput DNA methylation analysis with enhanced accuracy and speed. This system supports comprehensive epigenomic profiling for cancer and autoimmune diagnostics. Illumina expanded collaborations with leading academic and clinical research centers to accelerate biomarker discovery and clinical validation.

In May 2025, Thermo Fisher launched improved bisulfite conversion and methylation-specific PCR assay kits that simplify workflows for epigenetic biomarker analysis. The kits are designed for clinical labs and research institutions working on oncology and neurological disorders. Thermo Fisher also extended its global distribution network to increase accessibility.

In May 2025, QIAGEN launched automated DNA methylation analysis instruments and software in May 2025 aimed at clinical laboratories. The integrated solutions reduce hands-on time and improve reproducibility in epigenetic testing. QIAGEN engaged in partnerships with hospitals to integrate epigenetic diagnostics into personalized treatment pathways for cancer patients.

In April 2025, Merck expanded its epigenetics research product line in April 2025 with new antibodies and reagents targeting histone modifications. This expansion supports drug discovery and diagnostic research focused on epigenetic regulation mechanisms across multiple diseases.

Products Covered:

  • Reagents
  • Kits
  • Instruments
  • Enzymes
  • Services

Technologies Covered:

  • DNA Methylation
  • Histone Methylation
  • MicroRNA Modification
  • Chromatin Structures
  • Other Technologies

Applications Covered:

  • Oncology
  • Non-Oncology
  • Other Applications

End Users Covered:

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epigenetic Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Reagents
  • 5.3 Kits
    • 5.3.1 ChIP Sequencing Kit
    • 5.3.2 Bisulfite Conversion Kit
    • 5.3.3 RNA Sequencing Kit
    • 5.3.4 Whole Genomic Amplification Kit
  • 5.4 Instruments
  • 5.5 Enzymes
  • 5.6 Services

6 Global Epigenetic Diagnostics Market, By Technology

  • 6.1 Introduction
  • 6.2 DNA Methylation
  • 6.3 Histone Methylation
  • 6.4 MicroRNA Modification
  • 6.5 Chromatin Structures
  • 6.6 Other Technologies

7 Global Epigenetic Diagnostics Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
    • 7.2.1 Solid Tumors
    • 7.2.2 Liquid Tumors
  • 7.3 Non-Oncology
    • 7.3.1 Inflammatory Diseases
    • 7.3.2 Metabolic Diseases
    • 7.3.3 Infectious Diseases
    • 7.3.4 Cardiovascular Diseases
  • 7.4 Other Applications

8 Global Epigenetic Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Academic Research
  • 8.3 Clinical Research
  • 8.4 Hospitals & Clinics
  • 8.5 Pharmaceutical & Biotechnology Companies
  • 8.6 Other End Users

9 Global Epigenetic Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina Inc.
  • 11.2 Thermo Fisher Scientific
  • 11.3 QIAGEN NV
  • 11.4 Merck KGaA (Merck Millipore)
  • 11.5 Agilent Technologies
  • 11.6 Bio-Rad Laboratories
  • 11.7 Abcam PLC
  • 11.8 PerkinElmer Inc.
  • 11.9 Active Motif
  • 11.10 Diagenode SA
  • 11.11 New England Biolabs
  • 11.12 Zymo Research Corporation
  • 11.13 F. Hoffmann-La Roche Ltd
  • 11.14 Novartis AG
  • 11.15 GlaxoSmithKline plc
  • 11.16 Eisai Co. Ltd.
  • 11.17 Pfizer Inc.
  • 11.18 Janssen Pharmaceuticals Inc.

List of Tables

  • Table 1 Global Epigenetic Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Epigenetic Diagnostics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Epigenetic Diagnostics Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 4 Global Epigenetic Diagnostics Market Outlook, By Kits (2024-2032) ($MN)
  • Table 5 Global Epigenetic Diagnostics Market Outlook, By ChIP Sequencing Kit (2024-2032) ($MN)
  • Table 6 Global Epigenetic Diagnostics Market Outlook, By Bisulfite Conversion Kit (2024-2032) ($MN)
  • Table 7 Global Epigenetic Diagnostics Market Outlook, By RNA Sequencing Kit (2024-2032) ($MN)
  • Table 8 Global Epigenetic Diagnostics Market Outlook, By Whole Genomic Amplification Kit (2024-2032) ($MN)
  • Table 9 Global Epigenetic Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 10 Global Epigenetic Diagnostics Market Outlook, By Enzymes (2024-2032) ($MN)
  • Table 11 Global Epigenetic Diagnostics Market Outlook, By Services (2024-2032) ($MN)
  • Table 12 Global Epigenetic Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 13 Global Epigenetic Diagnostics Market Outlook, By DNA Methylation (2024-2032) ($MN)
  • Table 14 Global Epigenetic Diagnostics Market Outlook, By Histone Methylation (2024-2032) ($MN)
  • Table 15 Global Epigenetic Diagnostics Market Outlook, By MicroRNA Modification (2024-2032) ($MN)
  • Table 16 Global Epigenetic Diagnostics Market Outlook, By Chromatin Structures (2024-2032) ($MN)
  • Table 17 Global Epigenetic Diagnostics Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 18 Global Epigenetic Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Epigenetic Diagnostics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Epigenetic Diagnostics Market Outlook, By Solid Tumors (2024-2032) ($MN)
  • Table 21 Global Epigenetic Diagnostics Market Outlook, By Liquid Tumors (2024-2032) ($MN)
  • Table 22 Global Epigenetic Diagnostics Market Outlook, By Non-Oncology (2024-2032) ($MN)
  • Table 23 Global Epigenetic Diagnostics Market Outlook, By Inflammatory Diseases (2024-2032) ($MN)
  • Table 24 Global Epigenetic Diagnostics Market Outlook, By Metabolic Diseases (2024-2032) ($MN)
  • Table 25 Global Epigenetic Diagnostics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 26 Global Epigenetic Diagnostics Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 27 Global Epigenetic Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 28 Global Epigenetic Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global Epigenetic Diagnostics Market Outlook, By Academic Research (2024-2032) ($MN)
  • Table 30 Global Epigenetic Diagnostics Market Outlook, By Clinical Research (2024-2032) ($MN)
  • Table 31 Global Epigenetic Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Epigenetic Diagnostics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 33 Global Epigenetic Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.